VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (the “Company or Cannabix”) developer of marijuana and alcohol breath testing technologies, is pleased to announce the deployment of its BreathLogix alcohol monitoring solution with the Lake County Community Corrections Program in Indiana. Lake County is Indiana’s second-most populous county, serving residents in the greater Chicago metropolitan region.
The BreathLogix system will support court-ordered alcohol monitoring initiatives administered by Lake County’s community corrections program staff. The deployment is designed to assist program administrators in monitoring participant compliance with court-imposed abstinence requirements while improving operational efficiency and reducing administrative burden.
Under the program, participants are required to undergo scheduled or random alcohol testing as a condition of probation, treatment, pre-trial release, or other court-supervised programs. The deployment is being facilitated by AlcoPro, Inc., an authorized reseller.
Under the program, participants may be required to undergo scheduled or random alcohol testing as a condition of probation, diversion, treatment, pre-trial release, or other court-supervised programs. BreathLogix enables participants to provide breath samples autonomously while maintaining identity verification through integrated photo capture technology.
BreathLogix rapidly screens for alcohol using a breath sample while simultaneously capturing a photograph of the user for identity verification. The system provides precise Blood Alcohol Content (BAC / BrAC) readings and can automatically deliver real-time alerts via SMS and email to designated program administrators when positive results are detected.
The deployment further expands Cannabix’s presence within the U.S. corrections, probation, treatment, and public safety markets where organizations are seeking automated alcohol testing solutions that improve compliance oversight while reducing staffing requirements.
Figure 1. BreathLogix Alcohol device available with for County Sobriety Programs
BreathLogix supports a broad range of alcohol monitoring applications, including:
- Court-ordered alcohol monitoring
- Probation and parole programs
- Pre-trial release supervision
- Diversion and specialty court programs
- Treatment and recovery programs
- Random and scheduled alcohol testing
- Workplace and safety-sensitive screening
- Return-to-work and fitness-for-duty assessments
By enabling frequent, reliable and automated alcohol screening, BreathLogix helps courts, treatment providers and supervision agencies strengthen compliance monitoring, improve participant accountability and enhance public safety outcomes.
Marketing Agreement
The Company has entered into a marketing services agreement (the “Agreement”) with Outside the Box Capital Inc. (“OTBC”), an arm’s-length marketing firm based in Oakville, Ontario. Pursuant to the Agreement, OTBC will provide marketing services, including social media marketing, content planning and creation, and the production and distribution of feature content regarding the Company through OTBC’s proprietary media channels and selected third-party platforms. The Agreement is effective September 9, 2026, for a term of six months. In consideration for the services to be provided under the Agreement, the Company has agreed to pay OTBC a one-time cash fee of $150,000 plus applicable taxes and 335,000 stock options (the “Options”) to acquire common shares of the Company at an exercise price of $0.45 per share for a period of one year from the date of grant. The Options will vest in accordance with the policies of the Canadian Securities Exchange and the Company’s equity incentive plan. Any common shares issued upon the exercise of the Options will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws.
OTBC is controlled by Jason Coles. OTBC and Mr. Coles are arm’s-length parties to the Company. Other than the Options described above, neither OTBC nor Mr. Coles currently holds any direct or indirect interest in the Company or its securities. OTBC has no relationship with the Company other than pursuant to the Agreement described in this news release.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—in breath, providing a practical solution for identifying recent marijuana use.
The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.com
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at [email protected]
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “may,” “will,” “could,” “should,” “potential,” and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements regarding: the anticipated benefits, performance and adoption of the Company’s BreathLogix alcohol monitoring system; the expected use of the system by community corrections agencies and other public sector organizations; the Company’s ability to expand deployments of BreathLogix in the United States and other jurisdictions; the commercialization and market acceptance of the Company’s products and technologies; the Company’s ability to enter into additional customer, distribution, service, or strategic partnership agreements; and the Company’s ongoing business, product development and financing plans. Forward-looking statements are based on management’s current expectations, assumptions and beliefs and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such factors include, without limitation: the ability of the Company to successfully deploy and support its technologies; customer adoption and retention; regulatory developments; changes in government procurement practices or community corrections requirements; competitive developments; technological advancements by competitors; economic and market conditions; the availability of financing; and other risks detailed from time to time in the Company’s public disclosure documents. There can be no assurance that the Company’s products will achieve commercial acceptance, that existing deployments will lead to additional contracts or revenue opportunities, or that any anticipated business objectives, strategic initiatives, partnerships, or growth opportunities will be realized. Actual results may differ materially from those currently anticipated in such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and are based on the beliefs, estimates, expectations and opinions of management on the date such statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c280215e-c351-42df-b85c-5f581f46994e
